Table 2.
Any Grade (N = 53) | Grade ≥3 (n = 26) | |
---|---|---|
Preferred term adverse event | ||
Bradycardia | 22 (42) | |
Myalgia | 16 (30) | |
Edema | 7 (13) | |
Preferred term for severe adverse events | ||
CK elevation | 9 (17) | 3 (6) |
AST/ALT increase | 5 (9) | 3 (6) |
Bradycardia | 6 (11) | 1 (2) |
Myalgia | 6 (11) | — |
Creatinine increase | 3 (6) | — |
Blood bilirubin increase | 2 (4) | 2 (4) |
Skin rash | 2 (4) | 2 (4) |
Fatigue | 1 (2) | — |
Edema | 2 (4) | — |
Pneumonitis | 1 (2) | — |
Severe toxicity consequence | ||
Hospital admission | 1 (2) | |
Dose reduction | 25 (47) | |
Treatment interruption | 17 (32) | |
Treatment termination | 2 (4) |
Values are n (%).
AST = aspartate aminotransferase; ALT = alanine aminotransferase; CK = creatine kinase.